FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks
Several FDA advisors said there could be a significant safety issue after two vaccine recipients out of about 20,000 developed Guillain-Barre syndrome.
Several FDA advisors said there could be a significant safety issue after two vaccine recipients out of about 20,000 developed Guillain-Barre syndrome.
